Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA advisory committee backs AstraZeneca’s albuterol/budesonide for asthma

By Brian Buntz | November 10, 2022

AstraZenecaFDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 16 to 1 in favor of the albuterol/budesonide (PT027) from AstraZeneca (Nasdaq:AZN) to treat asthma in people at least 18 years old.

The voting proposition asked whether the data supported a favorable benefit-risk assessment for various age groups.

The advisory committee did not endorse albuterol/budesonide for patients 12 to 17 years old or those 4 to 11. For the former age group, nine members voted that the data do not support a favorable benefit-risk assessment. For 4- to 11-year-olds, 16 members voted against the measure, while one voted for it.

AstraZeneca is developing PT027 in collaboration with London-based Avillion.

In the U.S., the drug candidate would be a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication.

Albuterol, also known as salbutamol, was first discovered in 1966. Albuterol is a short-acting beta2-agonist (SABA).

Budesonide is an anti-inflammatory inhaled corticosteroid (ICS). An extended-release tablet-based version of the drug has won FDA approval for ulcerative colitis.

FDA accepted the New Drug Application (NDA) for PT027 in the first half of 2022.

The agency set a PDUFA date for the drug candidate in the first half of 2023.

“Millions of people with asthma rely on their albuterol rescue inhaler to alleviate acute symptoms, but this does not treat the underlying inflammation, leaving patients at risk of severe asthma exacerbations, regardless of their disease severity or level of control,” said Dr. Bradley E. Chipps, medical director of the Capital Allergy & Respiratory Disease Center in Sacramento, California. “If approved, PT027 could transform the current rescue treatment approach.”

AstraZeneca submitted data from the MANDALA, DENALI and TYREE Phase 3 studies as part of its FDA submission.

The New England Journal of Medicine published results from the MANDALA study in May 2022.

In that study, PT027 reduced the risk of a severe exacerbation relative to albuterol alone by 27% in asthma patients.


Filed Under: Allergists, Pulmonology
Tagged With: albuterol/budesonide
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Alex Zhavoronkov
Q&A: How Insilico Medicine’s AI identified a new IPF drug target in record time
Human Circulatory System Heart Anatomy
Fixed-dose macitentan-tadalafil polypill outperforms monotherapies in PAH
Insilico's AI-powered robotics lab
CEO: Insilico on how AI can ‘imagine the perfect molecules’ for drug targets
Insilico Medicine
Insilico’s AI-discovered INS018_055 graduates to phase 2
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE